Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 3/2020

01-04-2020 | Breast Cancer | Epidemiology

The spectrum of BRCA1 and BRCA2 mutations and clinicopathological characteristics in Chinese women with early-onset breast cancer

Authors: Lili Chen, Fangmeng Fu, Meng Huang, Jinxing Lv, Wenzhe Zhang, Chuan Wang

Published in: Breast Cancer Research and Treatment | Issue 3/2020

Login to get access

Abstract

Purpose

BRCA1/2 mutations represent a high risk of breast cancer and are related to early-onset breast cancer. However, few studies have reported the relationship between BRCA1/2 mutations and their clinical characteristics in early-onset breast cancers. This study is the first article that characterizes the risk factor profiles in Chinese patients selected by the age of onset (≤ 40 years old). We found some differences in the prevalence of germline BRCA1/2 mutations between Asian and Western countries.

Methods

A total of 1371 consecutive unselected Chinese early-onset breast cancer patients were enrolled from the Fujian Medical University Union Hospital, China, and screened for germline BRCA1/2 mutations. Full-exome sequencing in next-generation sequencing technology was performed in all patients to examine BRCA1/2 mutations.

Results

In our study, 25 (1.8%) and 61 (4.4%) patients were identified with BRCA1 and BRCA2 mutations, respectively, among the unselected early-onset breast cancer patients. BRCA1 mutations were associated with pregnancies (p = 0.026), and BRCA1 carriers had a higher likelihood of being HR positive (p < 0.001), HER2 negative (p < 0.001), or high grade (p = 0.002) than noncarriers. Among BRCA2 mutations, the age of onset was younger in carriers than in noncarriers (p = 0.017), and BRCA2 carriers were more likely to have lymph node metastasis (p = 0.004). HR-positive or HER2-negative patients were likely to be positive for BRCA2 mutations (p < 0.001). Overall, 14 BRCA1 mutations and 8 BRCA2 mutations were first reported in our study

Conclusion

This study provided some information about the spectrum of BRCA1/2 mutations and characterized the risk factors for early-onset breast cancer in China.
Literature
1.
Assi HA, Khoury KE, Dbouk H, Khalil LE, Mouhieddine TH, El Saghir NS (2013) Epidemiology and prognosis of breast cancer in young women. J Thorac Dis 5(1):S2–S8PubMedPubMedCentral
2.
3.
4.
Shuch B, Vourganti S, Ricketts CJ, Middleton L, Peterson J, Merino MJ et al (2014) Defining early-onset kidney cancer: implications for germline and somatic mutation testing and clinical management. J Clin Oncol 32(5):431–437CrossRefPubMed
5.
Rosenberg Shoshana M, Kathryn J, Ruddy Rulla M et al (2016) BRCA1 and BRCA2 mutation testing in young women with breast cancer. JAMA Oncol 2(6):730–736CrossRefPubMedPubMedCentral
6.
Chuang C, Sun S, Jing-Ping Y, Yao-Huai W, Yi T, Feng Y et al (2016) Characteristics of breast cancer in Central China, literature review and comparison with USA. Breast 30:208–213CrossRef
7.
Anders CK, Hsu DS, Broadwater G et al (2008) Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol 26:3324–3330CrossRefPubMed
8.
Soley B, Banu A (2016) BRCA mutation genetic testing implications in the United States. Breast 31:224–232
9.
10.
Young SR, Pilarski RT, Donenberg T et al (2009) The prevalence of BRCA1 mutations among young women with triple negative breast cancer. BMC Cancer 9:1–5CrossRef
11.
Anglian Breast Cancer Study Group (2000) Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Br J Cancer 83(10):1301–1308CrossRefPubMedCentral
12.
Yang XR, Devi BCR, Sung H et al (2017) Prevalence and spectrum of germline rare variants in BRCA1/2 and PALB2 among breast cancer cases in Sarawak. Breast Cancer Res Treat 165(3):687–697CrossRefPubMedPubMedCentral
13.
Rennert G, Bisland-Naggan S, Barnett-Griness O et al (2007) Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 357(2):115–123CrossRefPubMed
14.
Verhoog LC, Brekelmans CT, Seynaeve C et al (1998) Survival and tumour characteristics of breast cancer patients with germline mutations of BRCA1. Lancet 351:316–321CrossRefPubMed
15.
Huzarski T, Byrski T, Gronwald J et al (2013) Ten year survival in patients with BRCA1-negative and BRCA1-positive breast cancer. J Clin Oncol 31:3191–3196CrossRefPubMed
16.
Bordeleau L, Panchal S, Goodwin P (2010) Prognosis of BRCA-associated breast cancer: a summary of evidence. Breast Cancer Res Treat 119:13–24CrossRefPubMed
17.
Claus EB, Schildkraut JM, Thompson WD, Risch NJ (1996) The genetic attributable risk of breast and ovarian cancer. Cancer 77:2318–2324CrossRefPubMed
18.
Jie S, Hua M, Lu Y, Meng L, Xie Y et al (2017) Germline mutations in cancer susceptibility genes in a large series of unselected breast cancer patients. Clin Cancer Res 23(20):6113–6119CrossRef
19.
Lang GT, Shi JX, Hu X, Zhang CH, Shan L, Shao ZM (2017) The spectrum of BRCA mutations and characteristics of BRCA-associated breast cancers in China: screening of 2991 patients and 1043 controls by next-generation sequencing. Int J Cancer 141(1):129–142CrossRefPubMed
20.
Rebbeck TR, Mitra N, Wan F, Sinilnikova OM, Healey S, McGuffog L, Mazoyer S, Chenevix-Trench G, Easton DF, Antoniou AC, Nathanson KL (2015) The CIMBA consortium, association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA 313(13):1347–1361CrossRefPubMedPubMedCentral
21.
Wojcik P, Jasiowka M, Strycharz E, Sobol M, Hodorowicz-Zaniewska D, Skotnicki P, Pierzchalski P (2016) Recurrent mutations of BRCA1, BRCA2 and PALB2 in the population of breast and ovariancancer patients in Southern Poland. Hered Cancer Clin Pract 14:5CrossRefPubMedPubMedCentral
22.
Caux-Moncoutier V, Pages-Berhouet S, Michaux D, Asselain B, Houdayer C (2009) Impact of BRCA1 and BRCA2 variants on splicing: clues from an allelic imbalance study. Eur J Hum Genet 17(11):1471–1480CrossRefPubMedPubMedCentral
23.
Kim YC, Zhao L, Zhang H, Huang Y, Cui J, Xiao F, Downs B, Wang SM (2016) Prevalence and spectrum of BRCA germline variants in mainland Chinese familial breast and ovarian cancer patients. Oncotarget 7(8):9600–9612CrossRefPubMedPubMedCentral
24.
Yang X, Wu J, Lu J, Liu G, Di G, Chen C, Sun M, Hu Z (2015) Identification of a comprehensive spectrum of genetic factors for hereditary breast cancer in a Chinese population by next-generation sequencing. PLoS ONE 10(4):30125571
25.
Li WF, Hu Z, Rao NY, Song CG, Zhang B, Shao ZM (2008) The prevalence of BRCA1 and BRCA2 germline mutations in high-risk breast cancer patients of Chinese Han nationality: two recurrent mutations were identified. Breast Cancer Res Treat 110(1):99–109CrossRefPubMed
26.
Suter NM, Ray RM, Hu YW, Lin MG, Porter P (2004) BRCA1 and BRCA2 mutations in women from Shanghai China. Cancer Epedemiol Biomarkers Prev 13(2):181–189CrossRef
27.
Bergman A, Flodin A, Engwall Y, Arkblad EL, Berg K, Einbeigi Z (2005) A high frequency of germline BRCA1/2 mutations in western Sweden detected with complementary screening techniques. Fam Cancer 4(2):89–96CrossRefPubMed
28.
Zhang J, Sun J, Chen J, Yao L, Ouyang T, Li J, Xie Y (2016) Comprehensive analysis of BRCA1 and BRCA2 germline mutations in a large cohort of 5931 Chinese women with breast cancer. Breast Cancer Res Treat 158(3):455–462CrossRefPubMed
29.
Lecarpentier J, Noguès C, Mouret-Fourme E, Gauthier-Villars M, Lasset C, Fricker JP (2012) Variation in breast cancer risk associated with factors related to pregnancies according to truncating mutation location, in the French National BRCA1 and BRCA2 mutations carrier cohort(GENEPSO). Breast Cancer Res 14(4):R99CrossRefPubMedPubMedCentral
30.
Kast K, Rhiem K, Wappenschmidt B, Hahnen E, Hauke J, Bluemcke B, Zarghooni V, Herold N, Ditsch N, Kiechle M, Braun M, Fischer C et al (2016) Prevalence of BRCA1/2 germline mutations in 21401 families with breast and ovarian cancer. J Med Genet 53:465–471CrossRefPubMed
31.
Peto J, Collins N, Barfoot R, Seal S, Warren W, Rahman N, Easton DF, Evans C, Deacon J, Stratton MR (1999) Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst 91:943–949CrossRefPubMed
32.
Copson ER, Maishman TC, Tapper WJ, Cutress RI, Greville-Heygate S (2018) Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospectivecohort study. Lancet Oncol 19(2):169–180CrossRefPubMedPubMedCentral
33.
Bayraktar S, Amendola L, Gutierrez-Barrera AM, Hashmi SS (2014) Clinicopathologic characteristics of breast cancer in BRCA-carriers and non-carriers in women 35 years of age or less. Breast 23(6):770–774CrossRefPubMed
34.
Brown KL, Hutchison R, Zinberg E, McGovern MM (2005) Referral and experience with genetic testing among women with early onset breast cancer. Genet Test 9(4):301–305CrossRefPubMed
35.
Ruddy KJ, Gelber S, Shin J, Garber JE (2010) Genetic testing in young women with breast cancer: results from a web-based survey. Ann Oncol. 21(4):741–747CrossRefPubMed
36.
Peters N, Domchek SM, Rose A, Polis R, Stopfer J, Armstrong K (2005) Knowledge, attitudes, and utilization of BRCA1/2 testing among women with early-onset breast cancer. Genet Test 9(1):48–53CrossRefPubMed
37.
Yao L, Sun J, Zhang J, He Y, Ouyang T, Xie Y (2016) Breast cancer risk in Chinese women with BRCA1 or BRCA2 mutations. Breast Cancer Res Treat 6(3):441–445CrossRef
38.
Moller P, Evans DG, Reis MM et al (2007) Surveillance for familial breast cancer: differences in outcome according to BRCA mutation status. Int J Cancer 121:1017–1020CrossRefPubMed
39.
(c)National Comprehensive Cancer Network, Inc., 2015. NCCN clinical practice guidelines in oncology (NCCN Guidelines®) for breast and/or ovarian cancer genetic assessment V.1.2019. National Comprehensive Cancer Network®, NCCN®, NCCN Guidelines®, and all other NCCN Content are Trademarks Owned by the National Comprehensive Cancer Network, Inc.
40.
Lakhani SR, Jacquemier J, Sloane JP et al (1998) Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst 90(15):1138–1145CrossRefPubMed
41.
Phillips KA (2000) Immunophenotypic and pathologic differences between BRCA1 and BRCA2 hereditary breast cancers. J Clin Oncol 18(21):107S–112SPubMed
42.
43.
Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry. Cancer 109(9):1721–1728CrossRefPubMed
44.
Frank TS, Deffenbaugh AM, Reid JE et al (2002) Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol 20(6):1480–1490CrossRefPubMed
45.
Gonzalez-Angulo AM, Broglio K, Kau SW et al (2005) Women age ≤ 35 years with primary breast carcinoma: disease features at presentation. Cancer 103(12):2466–2472CrossRefPubMed
46.
Tryggvadottir L, Tulinius H, Eyfjord JE, Sigurvinsson T (2002) Breast cancer risk factors and age at diagnosis: an Icelandic cohort study. Int J Cancer 98(4):604–608CrossRefPubMed
Metadata
Title
The spectrum of BRCA1 and BRCA2 mutations and clinicopathological characteristics in Chinese women with early-onset breast cancer
Authors
Lili Chen
Fangmeng Fu
Meng Huang
Jinxing Lv
Wenzhe Zhang
Chuan Wang
Publication date
01-04-2020
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2020
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-020-05573-x

Other articles of this Issue 3/2020

Breast Cancer Research and Treatment 3/2020 Go to the issue

Preclinical study

Targeted degradation of activating estrogen receptor α ligand-binding domain mutations in human breast cancer

Clinical Trial

Changes in bone mineral density during 5 years of adjuvant treatment in premenopausal breast cancer patients

Epidemiology

Trajectory of recurrent falls in post-menopausal breast cancer survivors and in matched cancer-free controls

Clinical trial

Phase II trial of eribulin in patients who do not achieve pathologic complete response (pCR) following neoadjuvant chemotherapy

Letter to the Editor

Clinical significance of gene mutation in ctDNA analysis for hormone receptor-positive metastatic breast cancer

Epidemiology

Adherence trajectories of adjuvant endocrine therapy in the five years after its initiation among women with non-metastatic breast cancer: a cohort study using administrative databases
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits